Skip to main content

Cancer Genetics, GeneCast Ink Cancer Test Distribution Deal

NEW YORK (GenomeWeb) — Cancer Genetics (CGI) said today that it signed a distribution deal for its microarray gene expression Tissue of Origin test in China with GeneCast Biotechnology.

According to Rutherford, New Jersey-based CGI, the test is designed to analyze 2,000 individual tumor genes, covering 15 of the most common tumor types and 90 percent of all solid tumors, in order to help identify a malignancy's origin.

Under the terms of the deal, Beijing-based GeneCast will have the exclusive rights to market, sell, and distribute the test in China. Additional terms were not disclosed.

"We are excited to make this test available to cancer patients in China through GeneCast's proven distribution capabilities in the space," CGI CEO John Roberts said in a statement. "This collaboration is in line with our business transformation strategy of driving sustainable, long-term growth and profitability by leveraging our unique assets."

Last month, Agendia named GeneCast as the exclusive marketer of its MammaPrint and BluePrint tests in China.